Skip to content
JoelGalvan

JoelGalvan

View Video Stories
  • Home
  • Business
  • Culture
  • Sports
  • Home
  • Business
  • Culture
  • Sports
© https://joelgalvan.site/-All rights reserved. Theme Blognest designed by WPInterface.
  • Home
  • Pharmaceuticals

Tag: Pharmaceuticals

Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia
Posted in Business

Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia

Estimated read time 2 min read
Posted on July 22, 2025
by Joelgalvan

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best small cap AI stocks to buy according to analysts. On July…

Learn More Leave a Comment on Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia
Jazz Pharmaceuticals (JAZZ) Highlights Growth at Goldman Sachs Healthcare Conference
Posted in Business

Jazz Pharmaceuticals (JAZZ) Highlights Growth at Goldman Sachs Healthcare Conference

Estimated read time 2 min read
Posted on July 16, 2025
by Joelgalvan

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) is one of the 7 most undervalued pot stocks to buy according to analysts. On June…

Learn More Leave a Comment on Jazz Pharmaceuticals (JAZZ) Highlights Growth at Goldman Sachs Healthcare Conference
Processa Pharmaceuticals, Inc. (PCSA) Secures Buy Rating on Portfolio Progress
Posted in Business

Processa Pharmaceuticals, Inc. (PCSA) Secures Buy Rating on Portfolio Progress

Estimated read time 2 min read
Posted on July 13, 2025
by Joelgalvan

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) is among the fundamentally strong penny stocks to invest in. Analysts at H.C. Wainwright have reiterated…

Learn More Leave a Comment on Processa Pharmaceuticals, Inc. (PCSA) Secures Buy Rating on Portfolio Progress
Barclays Upgrades Ionis Pharmaceuticals (IONS) Stock, Raises PT
Posted in Business

Barclays Upgrades Ionis Pharmaceuticals (IONS) Stock, Raises PT

Estimated read time 2 min read
Posted on July 11, 2025
by Joelgalvan

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. Barclays upgraded…

Learn More Leave a Comment on Barclays Upgrades Ionis Pharmaceuticals (IONS) Stock, Raises PT
Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today
Posted in Business

Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today

Estimated read time 2 min read
Posted on June 6, 2025
by Joelgalvan

We recently published a list of These 10 Stocks Are On Fire Right Now. In this article, we are going…

Learn More Leave a Comment on Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today
Biodexa Pharmaceuticals sees cash runway into 1Q26
Posted in Business

Biodexa Pharmaceuticals sees cash runway into 1Q26

Estimated read time 2 min read
Posted on June 1, 2025
by Joelgalvan

As of May 29, 2025, the Company had access to the following cash resources: Cash at bank $5.7M; Cash in…

Learn More Leave a Comment on Biodexa Pharmaceuticals sees cash runway into 1Q26
Truist Initiates Teva Pharmaceuticals (TEVA) Coverage with Buy, $25 Price Target
Posted in Business

Truist Initiates Teva Pharmaceuticals (TEVA) Coverage with Buy, $25 Price Target

Estimated read time 2 min read
Posted on May 31, 2025
by Joelgalvan

On Tuesday, May 27, an analyst from Truist Securities initiated coverage on Teva Pharmaceutical Industries Limited (NYSE:TEVA) with a Buy…

Learn More Leave a Comment on Truist Initiates Teva Pharmaceuticals (TEVA) Coverage with Buy, $25 Price Target
ORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 Trials
Posted in Business

ORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 Trials

Estimated read time 2 min read
Posted on May 30, 2025
by Joelgalvan

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) has unveiled promising early results from its Phase 1b trial of ORIC-944, a novel PRC2 inhibitor,…

Learn More Leave a Comment on ORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 Trials
Accretion Pharmaceuticals IPO listing today. Check GMP ahead of debut
Posted in Business

Accretion Pharmaceuticals IPO listing today. Check GMP ahead of debut

Estimated read time 2 min read
Posted on May 21, 2025
by Joelgalvan

Accretion Pharmaceuticals, a Gujarat-based pharma manufacturer, concluded its Rs 29.75 crore SME IPO on May 16. The issue, priced between…

Learn More Leave a Comment on Accretion Pharmaceuticals IPO listing today. Check GMP ahead of debut
Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer
Posted in Business

Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer

Estimated read time 1 min read
Posted on May 17, 2025
by Joelgalvan

Oppenheimer raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $19 from $17 and keeps a Perform rating on…

Learn More Leave a Comment on Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer

Posts navigation

← Older Articles

Recent Posts

  • Massive star who signed a new WWE deal will be involved in project outside the company
  • Here’s Why Resideo Technologies (REZI) Surged in Q2
  • England’s Chloe Kelly ‘thrives on’ producing the big moments after last-gasp heroics send Lionesses into Euro 2025 final, says Sarina Wiegman | Football News
  • Eternal: Eternal soars 10% as Blinkit reports strong performance
  • Curnow trade bombshell drops, Port great calls for prime time Showdown

Recent Comments

No comments to show.

Archives

  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025

Categories

  • Business
  • Culture
  • Sports
© https://joelgalvan.site/-All rights reserved. Theme Blognest designed by WPInterface.